26 completed, 23 recruiting, 11 terminated, 9 active not recruiting. 33 Phase 1, 30 Phase 2, 10 Phase 3, 3 Not applicable, 3 Phase 4.
Follow Prostatic Neoplasms, Castration-Resistant: new trials by email Literature Review of Prostatic Neoplasms, Castration-Resistant trials Research Report on Prostatic Neoplasms, Castration-Resistant
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pluvicto Real-world Investigation in Survival in Metastatic CRPC Prostatic Neoplasms, Castration-Resistant, Neoplasm Metastasis | Not yet recruiting | Novartis Pharmaceuticals | 1085 | 2026-10-15 | 2026-07-22 | |
| Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy 177Lu-PSMA-617 + SPECT/CT dosimetry - Carcinoma, Castration Resistant Prostatic Neoplasms | Not applicable | Not yet recruiting | Centre Henri Becquerel | 100 | 2026-09-01 | 2026-05-14 |
| Predictive Factors for Response to Lutetium-177 PSMA Radioligand Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer [177Lu]Lu-PSMA-617 (Pluvicto, Novartis), 68Ga-PSMA-11 PET/CT, Post-therapy 177Lu-PSMA SPECT/CT dosimetry - Prostate Cancer, Prostatic Neoplasms | Recruiting | Lithuanian University of Health Sciences | 70 | 2026-08-04 | 2026-10-14 | |
| A Study in Patients With Metastatic Castration-Resistant Prostate Cancer FX-111 - Metastatic Castration Resistant Prostate Cancer, mCRPC | Phase 1 | Recruiting | Flare Therapeutics Inc. | 60 | 2026-07-01 | 2026-09-24 |
| A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer Prostatic Neoplasms, Castration-Resistant | Recruiting | Novartis Pharmaceuticals | 17111 | 2026-06-30 | 2026-10-15 | |
| A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan Prostatic Neoplasms, Castration-Resistant | Recruiting | Novartis Pharmaceuticals | 1067 | 2026-06-30 | 2026-10-15 | |
| A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer TD001 - Metastatic Castration-Resistant Prostatic Cancer | Phase 1 / Phase 2 | Recruiting | T.O.A.D. Oncology SA | 180 | 2026-01-30 | 2026-05-29 |
| Development and Prospective Validation of a Pathology-Based Artificial Intelligence Model for Predicting the Time to Castration Resistance of Prostate Cancer Artificial intelligence (AI)-based predictive model (developed) - Prostatic Neoplasms, Castration-Resistant | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 150 | 2026-01-01 | 2026-01-29 | |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer Pasritamig, Docetaxel, Prednisone/Prednisolone - Prostatic Neoplasms, Castration-Resistant | Phase 3 | Recruiting | Janssen Research & Development, LLC | 800 | 2025-12-19 | 2026-09-25 |
| A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) Pasritamig, Placebo, Best Supportive Care (BSC) - Metastatic Castration-resistant Prostatic Neoplasms | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1203 | 2025-09-02 | 2026-09-25 |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) JSB462, AAA617 - Prostatic Cancer, Castration-Resistant | Phase 2 | Active not recruiting | Novartis Pharmaceuticals | 138 | 2025-07-03 | 2026-10-09 |
| A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) Docetaxel, Ifinatamab Deruxtecan, Opevesostat - Castration-Resistant Prostatic Cancer, Metastasis | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 360 | 2025-07-03 | 2026-10-09 |
| A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring JNJ-75348780, JNJ-67856633, JNJ-54179060 - Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Enrolling by invitation | Janssen Research & Development, LLC | 120 | 2024-12-30 | 2026-09-25 |
| 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer 18F-Fluciclovine PET/CT Scan - Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 4 | Recruiting | VA Greater Los Angeles Healthcare System | 15 | 2024-12-15 | 2024-11-27 |
| Treatment With Darolutamide +/- Radiation Therapy for Patients With a Castration Resistant Cancer and Metastases Detected by Functional Imaging Darolutamide 300 mg, Stereotactic body radiation therapy, Androgen deprivation therapy - Prostatic Cancer, Castration-Resistant | Phase 3 | Recruiting | UNICANCER | 336 | 2024-10-07 | 2024-12-20 |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) Opevesostat, Olaparib, Docetaxel - Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 220 | 2024-05-20 | 2026-10-21 |
| Fractionated Stereotactic Radiotherapy Plus Second-generation Antiandrogen for Oligometastatic Castration-resistant Prostate Cancer Patients. Xtandi, Zytiga® (Abiraterone Acetate), SBRT - Prostatic Neoplasms, Castration-Resistant | Phase 2 | Recruiting | Instituto de Investigación en Oncología Radioterápica - Fundación Española de Oncología Radioterápic | 51 | 2024-05-16 | 2026-07-21 |
| A Study of MGC026 in Participants With Advanced Solid Tumors MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab - Advanced Solid Tumor, Advanced Cancer | Phase 1 | Recruiting | MacroGenics | 394 | 2024-03-06 | 2026-10-28 |
| An External Control Arm Study Comparing Survival Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With 177Lu-PSMA-617 vs Androgen Receptor Pathway Inhibitor (ARPI) Switch in Routine Care Castration-Resistant Prostatic Cancer | Completed | Novartis Pharmaceuticals | 1525 | 2024-03-01 | 2026-10-01 | |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer Gedatolisib, Darolutamide - mCRPC (Metastatic Castration-resistant Prostate Cancer), Genital Diseases, Male | Phase 1 / Phase 2 | Recruiting | Celcuity Inc | 54 | 2024-01-01 | 2026-04-13 |
Showing 20 of 85. Sign in to see all of them.
Prostatic Neoplasms (33) · Neoplasms (10) · Neoplasm Metastasis (7) · Neoplasms by Site (5) · Prostatic Diseases (5) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Melanoma (4) · Pancreatic Neoplasms (4) · Urogenital Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Non-Small-Cell Lung (3) · Endometrial Neoplasms (3) · Male Urogenital Diseases (3)
Genital Diseases (84) · Urogenital Diseases (84) · Male Urogenital Diseases (82) · Genital Diseases, Male (81) · Genital Neoplasms, Male (81) · Urogenital Neoplasms (81) · Neoplasms by Site (80) · Prostatic Diseases (80) · Neoplasms (75) · Prostatic Neoplasms (52) · Female Urogenital Diseases (10) · Female Urogenital Diseases and Pregnancy Complications (10) · Neoplasms, Glandular and Epithelial (9) · Neoplasms by Histologic Type (8) · Pathologic Processes (8)
enzalutamide (20) · Abiraterone Acetate (12) · Docetaxel (8) · Prednisone (7) · radium Ra 223 dichloride (6) · abiraterone (5) · darolutamide (4) · Pluvicto (3) · apalutamide (3) · Nivolumab (2) · atezolizumab (2) · cabazitaxel (2) · niraparib (2) · olaparib (2) · pembrolizumab (2)
Janssen Research & Development, LLC (8) · Bayer (7) · Novartis Pharmaceuticals (6) · MacroGenics (4) · Michael Graham PhD, MD (3) · Nuvation Bio Inc. (3) · Bristol-Myers Squibb (2) · Cancer Research UK (2) · Hoffmann-La Roche (2) · Merck Sharp & Dohme LLC (2) · Pfizer (2) · Radboud University Medical Center (2) · Aragon Pharmaceuticals, Inc. (1) · Arcus Biosciences, Inc. (1) · Astellas Pharma Global Development, Inc. (1)
United States (49) · Spain (20) · Australia (19) · France (19) · United Kingdom (18) · Canada (13) · Italy (13) · South Korea (13) · Germany (12) · Belgium (10) · Netherlands (10) · Taiwan (10) · Poland (9) · China (8) · Japan (7)
Alton O Sartor, MD (1) · David Nanus, M.D. (1) · David Oh, MD (1)
PMID 40016438, PMID 31446511, PMID 32878613, PMID 33067297, PMID 33575828, PMID 33836265, PMID 34645727, PMID 35013615, PMID 35110356, PMID 36952634, PMID 37385670, PMID 37889298, PMID 38287346, PMID 38485614, PMID 38769643, PMID 38782459, PMID 38958846, PMID 39008067, PMID 39111209, PMID 39293515, PMID 39317633, PMID 40619537, PMID 42015879, PMID 42389925, PMID 42558019, PMID 42864777
2023 (6), 2017 (3), 2025 (3), 2016 (2), 2019 (2), 2015 (1), 2018 (1), P30CA012197 (1), R01CA223484 (1)